AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1829732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 6872170 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (300 to 900 mg/day)
Number of subjects: 13
Study 6872170 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (900 mg/day)
Number of subjects: 13
Study 6872170 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 13
Study 30418157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary tenecteplase
Number of subjects: 76
Study 30418157 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 76
Study 28894292 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 60
Study 28894292 — intervention group
Group type: COMPARATOR
Intervention: Matched caloric restriction
Number of subjects: 60
Study 28894292 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy
Number of subjects: 60
Study 25197789 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular utilisation of preschools
Number of subjects: 599
Study 25197789 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 599
Study 25197789 — intervention group
Group type: EXPERIMENTAL
Intervention: Low parental socioeconomic status
Number of subjects: 599
Study 25197789 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adequate development of FM
Number of subjects: 599
Study 25295403 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart-Booking (algorithmically generated double-booking recommendations)
Number of subjects: 519
Study 25295403 — intervention group
Group type: COMPARATOR
Intervention: Control (usual booking rules)
Number of subjects: 519
Study 25295403 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart-Booking
Number of subjects: 519
Study 25295403 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 519
Study 25295403 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey response from physicians after each session
Number of subjects: 519
Study 23030574 — intervention group
Group type: EXPERIMENTAL
Intervention: Low literacy participants
Number of subjects: 975
Study 20592632 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic lacrimal duct recanalization (ELDR)
Number of subjects: 166
Study 20592632 — intervention group
Group type: COMPARATOR
Intervention: Standard external dacryocystorhinostomy (SE‐DCR)
Number of subjects: 166
Study 17882923 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 450
Study 17882923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 17882923 — intervention group
Group type: COMPARATOR
Intervention: Mometasone nasal spray
Number of subjects: 450
Study 16280286 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ (150/12.5 mg)
Number of subjects: 800
Study 16280286 — intervention group
Group type: COMPARATOR
Intervention: Valsartan/HCTZ (80/12.5 mg)
Number of subjects: 800
Study 11988719 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic acromioplasty
Number of subjects: 62
Study 11988719 — intervention group
Group type: COMPARATOR
Intervention: Open acromioplasty
Number of subjects: 62
Study 10465817 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured 14-day quit programme (Time to quit)
Number of subjects: 521
Study 10465817 — intervention group
Group type: COMPARATOR
Intervention: Another booklet describing four broad stages of quitting (Can quit)
Number of subjects: 521
Study 10465817 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Time to quit and Can quit)
Number of subjects: 521
Study 7604803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day
Number of subjects: 1810
Study 7604803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin + cholestyramine
Number of subjects: 1810
Study 7604803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1810
Study 2211130 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Health Cooperative of Puget Sound
Number of subjects: 0
Study 2211130 — intervention group
Group type: COMPARATOR
Intervention: Comparable fee‐for‐service insurance plans
Number of subjects: 0
Study 681061 — intervention group
Group type: EXPERIMENTAL
Intervention: Family practice nurse
Number of subjects: 0
Study 681061 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study 31195650 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote device-monitoring system (TM)
Number of subjects: 50
Study 31195650 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient visits (HM)
Number of subjects: 50
Study 31195650 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TM and HM)
Number of subjects: 50
Study 28407625 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapracorat 0.1% ointment
Number of subjects: 0
Study 28407625 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 28407625 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference drugs
Number of subjects: 0
Study 25820660 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion training (N = 13)
Number of subjects: 47
Study 25820660 — intervention group
Group type: COMPARATOR
Intervention: Stress inoculation training (N = 14)
Number of subjects: 47
Study 23958776 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal ultrasound screening
Number of subjects: 2011
Study 23958776 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective ultrasound screening
Number of subjects: 2011
Study 23958776 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination (control group)
Number of subjects: 2011
Study 21606094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation-based intervention
Number of subjects: 465
Study 21606094 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 465
Study 21606094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation-based intervention (non-English speakers)
Number of subjects: 465
Study 21606094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation-based intervention (black patients)
Number of subjects: 465
Study 19780001 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin‐A injection (25 U, 0.5 ml, once)
Number of subjects: 100
Study 19780001 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine injection (2 ml, 20 mg, 1% lidocaine, twice a week for one month)
Number of subjects: 100
Study 19780001 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS, 60 sessions)
Number of subjects: 100
Study 19780001 — intervention group
Group type: COMPARATOR
Intervention: Laser treatments (20 sessions)
Number of subjects: 100
Study 16122963 — intervention group
Group type: EXPERIMENTAL
Intervention: Lempel-Ziv complexity (two-symbol sequence conversion)
Number of subjects: 11
Study 16122963 — intervention group
Group type: EXPERIMENTAL
Intervention: Lempel-Ziv complexity (three-symbol sequence conversion)
Number of subjects: 11
Study 16122963 — intervention group
Group type: COMPARATOR
Intervention: Central tendency measure (CTM)
Number of subjects: 11
Study 15349707 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 4
Study 15349707 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 4
Study 15349707 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 4
Study 15349707 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 20 mg
Number of subjects: 4
Study 15349707 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 4
Study 11565402 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnet-on group (active treatment)
Number of subjects: 176
Study 11565402 — intervention group
Group type: COMPARATOR
Intervention: Magnet-off group (placebo control)
Number of subjects: 176
Study 9022871 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar drink (beer)
Number of subjects: 2
Study 9022871 — intervention group
Group type: COMPARATOR
Intervention: Unfamiliar drink (blue peppermint mixture)
Number of subjects: 2
Study 8179847 — intervention group
Group type: EXPERIMENTAL
Intervention: Head out of water immersion (HOI) for 2 hours
Number of subjects: 27
Study 3299763 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole theophylline tablets (Euphyllin Retard)
Number of subjects: 14
Study 3299763 — intervention group
Group type: EXPERIMENTAL
Intervention: Halved theophylline tablets (Euphyllin Retard)
Number of subjects: 14
Study 31223099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast infusion (1 h) of Zn (100 μmol)
Number of subjects: 39
Study 31223099 — intervention group
Group type: COMPARATOR
Intervention: Slow infusion (10 h) of Zn (100 μmol)
Number of subjects: 39
Study 31223099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast infusion (1 h) of Mn (1000 nmol)
Number of subjects: 39
Study 31223099 — intervention group
Group type: COMPARATOR
Intervention: Slow infusion (10 h) of Mn (1000 nmol)
Number of subjects: 39
Study 31223099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast infusion (1 h) of Se (1 μmol)
Number of subjects: 39
Study 31223099 — intervention group
Group type: COMPARATOR
Intervention: Slow infusion (10 h) of Se (1 μmol)
Number of subjects: 39
Study 31223099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast infusion (1 h) of Cr (200 nmol)
Number of subjects: 39
Study 31223099 — intervention group
Group type: COMPARATOR
Intervention: Slow infusion (10 h) of Cr (200 nmol)
Number of subjects: 39
Study 31223099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast infusion (1 h) of Cu (8 μmol)
Number of subjects: 39
Study 31223099 — intervention group
Group type: COMPARATOR
Intervention: Slow infusion (10 h) of Cu (8 μmol)
Number of subjects: 39
Study 31223099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast infusion (1 h) of Fe (20 μmol)
Number of subjects: 39
Study 31223099 — intervention group
Group type: COMPARATOR
Intervention: Slow infusion (10 h) of Fe (20 μmol)
Number of subjects: 39
Study 29880231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 2 years
Number of subjects: 592
Study 29880231 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (standard-dose)
Number of subjects: 592
Study 29880231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 592
Study 29880231 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 592
Study 26857909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein antral isolation (PVAI) in sinus rhythm after direct current cardioversion
Number of subjects: 90
Study 26857909 — intervention group
Group type: COMPARATOR
Intervention: PVAI and ablation targeting complex-fractionated atrial electrograms while in AF
Number of subjects: 90
Study 26857909 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 ablation
Number of subjects: 90
Study 25100336 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kVp, 2.2 pitch, 20 ml of contrast medium and sinogram affirmed iterative reconstruction
Number of subjects: 100
Study 25100336 — intervention group
Group type: COMPARATOR
Intervention: 100 kVp, 1.2 pitch, 60 ml of contrast medium and filtered back projection algorithm
Number of subjects: 100
Study 22093187 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously every 4 weeks
Number of subjects: 1432
Study 22093187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1432
Study 20818194 — intervention group
Group type: EXPERIMENTAL
Intervention: lower limb exercise (HEEL)
Number of subjects: 6
Study 20818194 — intervention group
Group type: EXPERIMENTAL
Intervention: compression garment (TROU)
Number of subjects: 6
Study 20818194 — intervention group
Group type: COMPARATOR
Intervention: no intervention (CONTROL)
Number of subjects: 6
Study 17375862 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic disease management models for depression in primary care
Number of subjects: 0
Study 15266171 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc tetrofosmin scintigraphy
Number of subjects: 27
Study 15266171 — intervention group
Group type: COMPARATOR
Intervention: Control group (37 patients without bone marrow pathology)
Number of subjects: 27
Study 10812854 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (bladder training and pelvic floor muscle training)
Number of subjects: 0
Study 10812854 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (bladder training)
Number of subjects: 0
Study 10812854 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (pelvic floor muscle training)
Number of subjects: 0
Study 9113175 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 12.5 mg + 10 micrograms fentanyl subarachnoidally
Number of subjects: 100
Study 9113175 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 12.5 mg + saline subarachnoidally
Number of subjects: 100
Study 9113175 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 100 mg + 100 micrograms fentanyl epidurally
Number of subjects: 100
Study 9113175 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 100 mg + saline epidurally
Number of subjects: 100
Study 9113175 — intervention group
Group type: COMPARATOR
Intervention: Control (saline) subarachnoidally
Number of subjects: 100
Study 9113175 — intervention group
Group type: COMPARATOR
Intervention: Control (saline) epidurally
Number of subjects: 100
Study 1350428 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1600 IU/day)
Number of subjects: 21
Study 1350428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3928213 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous TRH/domperidone administration
Number of subjects: 6
Study 3928213 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH administration at 120 min during domperidone infusion
Number of subjects: 6
Study 3928213 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone administered at 120 min during TRH infusion
Number of subjects: 6
Study 3928213 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH administered at 120 min during TRH infusion
Number of subjects: 6
Study 3301785 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin inhalation (1 million units twice daily for three months)
Number of subjects: 40
Study 3301785 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation (isotonic saline)
Number of subjects: 40
Study 3301785 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin inhalation
Number of subjects: 40
Study 3301785 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 40
Study 30984320 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal appliance (OA) with nonsteroidal anti‐inflammatory drug (NSAID) therapy (nimesulide)
Number of subjects: 90
Study 30984320 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal appliance with dry needling (DN)
Number of subjects: 90
Study 30984320 — intervention group
Group type: COMPARATOR
Intervention: Occlusal appliance (OA-control group)
Number of subjects: 90
Study 29136001 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Intervention Strategy (CIS)
Number of subjects: 2004
Study 29136001 — intervention group
Group type: EXPERIMENTAL
Intervention: CIS+ (enhanced CIS with financial incentives)
Number of subjects: 2004
Study 29136001 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 2004
Study 26113687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (125 mg twice daily)
Number of subjects: 334
Study 26113687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 23145999 — intervention group
Group type: EXPERIMENTAL
Intervention: LF-PSu dialyzer
Number of subjects: 170
Study 23145999 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-PSu dialyzer
Number of subjects: 170
Study 23145999 — intervention group
Group type: EXPERIMENTAL
Intervention: PUR-H dialyzer
Number of subjects: 170
Study 23145999 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance hemodialysis patients
Number of subjects: 170
Study 23145999 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 170
Study 21552185 — intervention group
Group type: EXPERIMENTAL
Intervention: ART deferred until CD4 < 25% or severe HIV disease (group 1, n = 20)
Number of subjects: 54
Study 21552185 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation within 6 to 12 weeks of age (group 2, n = 34)
Number of subjects: 54
Study 21552185 — intervention group
Group type: COMPARATOR
Intervention: HIV-exposed uninfected infants (controls, n = 22)
Number of subjects: 54
Study 21552185 — intervention group
Group type: EXPERIMENTAL
Intervention: All HIV-infected infants with ART
Number of subjects: 54
Study 18077134 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/d of supplemental Zn
Number of subjects: 48
Study 18077134 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d of supplemental Zn
Number of subjects: 48
Study 18077134 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/d of supplemental Zn (placebo)
Number of subjects: 48
Study 17060762 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure closure (NPC) dressing connected to central aspiration system at -80 mm Hg
Number of subjects: 60
Study 17060762 — intervention group
Group type: COMPARATOR
Intervention: Control group with similar dressing but without connection to negative pressure
Number of subjects: 60
Study 15364188 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory intervention with women's groups
Number of subjects: 28931
Study 15364188 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28931
Study 11011299 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening in women with a family history of breast cancer
Number of subjects: 29179
Study 9292842 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, guideline-based reminders for corollary orders
Number of subjects: 89
Study 9292842 — intervention group
Group type: COMPARATOR
Intervention: No reminders about corollary orders (Control)
Number of subjects: 89
Study 9292842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 89
Study 8357194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (5 mg/kg per body weight in divided doses)
Number of subjects: 39
Study 8357194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8357194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 39
Study 3094562 — intervention group
Group type: EXPERIMENTAL
Intervention: medrysone (1%)
Number of subjects: 38
Study 3094562 — intervention group
Group type: COMPARATOR
Intervention: sodium cromoglycate (2%)
Number of subjects: 38
Study 30158221 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-year universal school-based resilience intervention targeting student resilience protective factors (2012-2014)
Number of subjects: 3155
Study 30158221 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 3155
Study 27912933 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Meditation (n=20), 8-week program, 1 hour weekly meetings
Number of subjects: 41
Study 27912933 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list, n=21)
Number of subjects: 41
Study 22956670 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 59
Study 22956670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 23900047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18264
Study 20413966 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet/training program
Number of subjects: 28
Study 18424598 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g of pureed strawberries (15 micromol anthocyanin)
Number of subjects: 12
Study 18424598 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 g of pureed strawberries (30 micromol anthocyanin)
Number of subjects: 12
Study 18424598 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 g of pureed strawberries (60 micromol anthocyanin)
Number of subjects: 12
Study 16623404 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-circuit anesthesia (CCA)
Number of subjects: 27
Study 16623404 — intervention group
Group type: COMPARATOR
Intervention: Semiclosed anesthesia (SCA)
Number of subjects: 27
Study 12803261 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral index monitoring
Number of subjects: 30
Study 12803261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bispectral index monitoring visible to anaesthesiologist)
Number of subjects: 30
Study 10910870 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (4 microg/kg)
Number of subjects: 12
Study 10910870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 12
Study 8807692 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community rehabilitation program
Number of subjects: 110
Study 8807692 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based rehabilitation programs
Number of subjects: 110
Study 1314871 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Number of subjects: 0
Study 3902184 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 100 mg twice a day
Number of subjects: 32
Study 3902184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30629589 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest Classifier
Number of subjects: 324
Study 30629589 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Tree Classifier focusing on lung side and platelet count
Number of subjects: 324
Study 30106883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/d for 4 weeks, then flexible dose up to 200 mg/d if needed.
Number of subjects: 77
Study 30106883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 30106883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 77
Study 26987056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention follow‐on formula (IF, 2.1g isomaltulose (Palatinose™)/100mL)
Number of subjects: 50